Allergic rhinitis

Area of Science:

• Immunology
• Pharmacology
• Clinical Medicine

Background:

• Allergic rhinitis treatment largely relies on symptomatic relief with antihistamines and nasal glucocorticoids.
• Recent years have seen minimal changes in pharmacological interventions for allergic rhinitis.
• The Finnish National Allergy Program has influenced treatment strategies over the past decade.

Purpose of the Study:

• To review current treatment strategies for allergic rhinitis.
• To highlight the role of hyposensitization as a disease-modifying therapy.
• To discuss the impact of new sublingual hyposensitization products on treatment accessibility and patient care.

Main Methods:

• Literature review of recent advancements in allergic rhinitis treatment.
• Analysis of the impact of national allergy programs on treatment strategies.
• Evaluation of hyposensitization, including sublingual immunotherapy, as a therapeutic option.

Main Results:

• Pharmacological treatment remains symptomatic and individualized, with limited new product development.
• Sublingual hyposensitization offers an effective, safe, and disease-modifying treatment option.
• New sublingual products enhance treatment accessibility, shifting care to a home-based, patient-oriented model with long-term cost benefits, despite higher initial patient costs.

Conclusions:

• Current allergic rhinitis management focuses on symptom control, with hyposensitization as the sole disease-modifying therapy.
• Sublingual immunotherapy represents a significant advancement, improving patient-centered care and cost-effectiveness.
• While effective, the high unit cost of sublingual hyposensitization presents a barrier for some patients.